Matthew Seymour, MD: A Clinical Trialist’s Perspective

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Jul

Today In Oncology

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Related Videos

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Addition of Glofitamab to R-CHOP or Pola-R-CHP in Younger Patients With High-Risk LBCL

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

PPP2R1A Mutations Linked to Improved Immunotherapy Outcomes in Ovarian Clear Cell Carcinoma

Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer